Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Stock analysts at Wedbush upped their Q2 2022 earnings per share estimates for Inozyme Pharma in a research note issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior estimate of ($0.53). Wedbush currently has a “Outperform” rating and a $23.00 target price on the stock. Wedbush also issued estimates for Inozyme Pharma’s Q3 2022 earnings at ($0.48) EPS, Q4 2022 earnings at ($0.37) EPS, FY2022 earnings at ($1.85) EPS, Q1 2023 earnings at ($0.41) EPS, Q2 2023 earnings at ($0.44) EPS, Q3 2023 earnings at ($0.48) EPS, Q4 2023 earnings at ($0.52) EPS, FY2023 earnings at ($1.85) EPS, FY2024 earnings at ($0.70) EPS and FY2025 earnings at ($2.07) EPS.
Other equities research analysts have also recently issued reports about the company. HC Wainwright began coverage on Inozyme Pharma in a research report on Monday, February 7th. They issued a “buy” rating and a $33.00 price objective for the company. Needham & Company LLC assumed coverage on Inozyme Pharma in a report on Thursday, April 14th. They set a “buy” rating and a $23.00 price objective for the company.
Inozyme Pharma (NASDAQ:INZY – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.11.
In related news, Director Robert Lorne Hopfner bought 1,070,000 shares of Inozyme Pharma stock in a transaction on Tuesday, April 19th. The shares were purchased at an average price of $3.69 per share, for a total transaction of $3,948,300.00. Following the completion of the acquisition, the director now owns 2,661,154 shares in the company, valued at $9,819,658.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Henric Bjorn Bjarke bought 27,100 shares of Inozyme Pharma stock in a transaction on Tuesday, April 19th. The shares were bought at an average price of $3.69 per share, for a total transaction of $99,999.00. Following the acquisition, the chief operating officer now owns 80,626 shares of the company’s stock, valued at approximately $297,509.94. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 2,519,850 shares of company stock valued at $9,298,247. Corporate insiders own 11.29% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of INZY. Citigroup Inc. lifted its holdings in shares of Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company’s stock valued at $51,000 after purchasing an additional 8,853 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Inozyme Pharma by 16,531.3% during the 4th quarter. Wells Fargo & Company MN now owns 7,983 shares of the company’s stock valued at $54,000 after purchasing an additional 7,935 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Inozyme Pharma by 4,030.0% during the 4th quarter. Bank of America Corp DE now owns 11,853 shares of the company’s stock valued at $81,000 after purchasing an additional 11,566 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Inozyme Pharma during the 4th quarter valued at about $106,000. Finally, New York State Common Retirement Fund lifted its stake in Inozyme Pharma by 18.8% in the 3rd quarter. New York State Common Retirement Fund now owns 10,453 shares of the company’s stock valued at $121,000 after acquiring an additional 1,651 shares in the last quarter.
About Inozyme Pharma (Get Rating)
Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
- Get a free copy of the StockNews.com research report on Inozyme Pharma (INZY)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.